Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Neutral 0

Analysts Offer Insights on Healthcare Companies: P3 Health Partners (PIII) and Edwards Lifesciences (EW)

AI-generated analysis

πŸ“Š Analyst Ryan Langston from TD Cowen assigned a Hold rating to P3 Health Partners (PIII) with a price target of $14.00.

πŸ’° The company's shares closed last Thursday at $13.86, just below the analyst's target.

πŸ“‰ Langston's historical track record shows an average return of -4.8% and a 38.6% success rate on his Healthcare sector picks.

🀝 P3 Health Partners currently holds a Moderate Buy consensus with a $14.00 average price target representing 38.5% upside.

⚠️ A previous report from TipRanks – Anthropic upgraded the stock to Hold with a lower $3.50 price target on May 9.

🩺 Analyst Josh Jennings from TD Cowen maintained a Buy rating on Edwards Lifesciences (EW).

πŸ’΅ Edwards Lifesciences shares closed last Thursday at $83.20, well below the general street consensus of $97.86.

πŸ“ˆ The Street generally suggests a Strong Buy consensus for Edwards Lifesciences with an average price target of $97.86.

πŸ” This represents a 19.2% upside potential from current levels according to the aggregated analyst data.

πŸ”„ A prior report from TipRanks – PerPlexity reiterated a Buy rating on Edwards Lifesciences with a $96.00 price target.

πŸ₯ Both analysts cover the Healthcare sector, with Jennings also tracking companies like Anteris Technologies and Orchestra BioMed.

πŸ“° Additional headlines note P3 Health Partners' trading halt, earnings call signals for a turnaround, and recent debt exchange execution.

πŸ“‰ Lake Street previously raised its price target for P3 Health Partners to $14 from $4.

Bullish Signals
  • P3 Health Partners has an analyst consensus of Moderate Buy with a price target of $14.00, representing a 38.5% upside from current levels.
  • Lake Street recently raised the price target for P3 Health Partners to $14 from $4, indicating significant positive sentiment.
  • Edwards Lifesciences maintains a Strong Buy analyst consensus rating with an average price target of $97.86, offering a 19.2% upside potential.
  • TD Cowen analyst Josh Jennings maintained a Buy rating on Edwards Lifesciences, reinforcing the stock's positive outlook.
Risk Factors
  • Analyst Ryan Langston assigned a Hold rating to P3 Health Partners with a price target of $14.00, while the company's shares closed at $13.86.
  • Analyst Josh Jennings from TD Cowen maintained a Buy rating on Edwards Lifesciences, but his personal track record shows an average return of 0.0% and a 43.8% success rate.
Full Analysis
Analysts from TD Cowen provided new ratings on healthcare stocks P3 Health Partners (PIII) and Edwards Lifesciences (EW). Ryan Langston assigned a Hold rating to P3 Health Partners with a price target of $14.00, while Josh Jennings maintained a Buy rating on Edwards Lifesciences with the company's shares closing at $83.20. The consensus for Edwards Lifesciences remains Strong Buy with an average price target of $97.86, representing 19.2% upside from current levels. For P3 Health Partners, the analyst consensus is Moderate Buy with a price target of $14.00, which is a 38.5% upside from current levels.